MX9604635A - Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento. - Google Patents
Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.Info
- Publication number
- MX9604635A MX9604635A MX9604635A MX9604635A MX9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A
- Authority
- MX
- Mexico
- Prior art keywords
- growth hormone
- patient
- igf
- serum level
- below normal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a métodos para incrementar el índice de crecimiento de un paciente humano que padezca el síndrome de insensibilidad parcial a la hormona del crecimiento, pero no síndrome de Laron. Uno de tales métodos comprende administrar una dosis efectiva de hormona del crecimiento, de preferencia hormona del crecimiento con una secuencia nativa, con o sin una metionina N-terminal, al paciente. El paciente se caracteriza por tener una estatura menor de aproximadamente -2 desviaciones estándar por abajo de lo normal para la edad y sexo, un nivel sérico de proteína de union a la hormona del crecimiento de alta afinidad que está cuando menos desviaciones estándar por abajo de los niveles normales, un nivel sérico de FCI-I que está por abajo de los niveles promedio normales y un nivel sérico de hormona del crecimiento que es cuando menos normal. En otro método, la misma poblacion de pacientes es tratada con una cantidad efectiva de FCI-I, administrada sola o en combinacion con una cantidad de hormona del crecimiento que sea efectiva en combinacion con el FCI-I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/224,982 US5646113A (en) | 1994-04-07 | 1994-04-07 | Treatment of partial growth hormone insensitivity syndrome |
PCT/US1995/003731 WO1995027495A2 (en) | 1994-04-07 | 1995-03-24 | Treatment of partial growth hormone insensitivity syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9604635A true MX9604635A (es) | 1997-11-29 |
Family
ID=22843052
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9604635A MX9604635A (es) | 1994-04-07 | 1995-03-24 | Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento. |
MX9701916A MX9701916A (es) | 1994-04-07 | 1995-03-24 | Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9701916A MX9701916A (es) | 1994-04-07 | 1995-03-24 | Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5646113A (es) |
EP (1) | EP0754048B1 (es) |
JP (2) | JP3366644B2 (es) |
AT (1) | ATE203165T1 (es) |
CA (1) | CA2187274C (es) |
DE (1) | DE69521796T2 (es) |
DK (1) | DK0754048T3 (es) |
ES (1) | ES2160704T3 (es) |
GR (1) | GR3036901T3 (es) |
MX (2) | MX9604635A (es) |
PT (1) | PT754048E (es) |
WO (1) | WO1995027495A2 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6207640B1 (en) * | 1994-04-07 | 2001-03-27 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0106565D0 (en) * | 2001-03-16 | 2001-05-09 | Leuven K U Res & Dev | Growth hormone treatment |
US20030143191A1 (en) * | 2001-05-25 | 2003-07-31 | Adam Bell | Chemokine beta-1 fusion proteins |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MXPA04012496A (es) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
BRPI0410164A (pt) | 2003-05-09 | 2006-05-16 | Neose Technologies Inc | composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
DK2274978T3 (en) * | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
KR101439880B1 (ko) | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
JP5460958B2 (ja) * | 2004-03-17 | 2014-04-02 | アンチキャンサー インコーポレーテッド | タンパク質ポリエチレングリコール(peg)複合体形成を増大させる方法 |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
WO2006105426A2 (en) * | 2005-03-30 | 2006-10-05 | Neose Technologies, Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
EP2386571B1 (en) * | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5216580B2 (ja) * | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
EP1901770B1 (en) * | 2005-06-02 | 2014-12-24 | Ipsen Biopharmaceuticals, Inc. | Gh and igf-1 for treatment of growth disorders |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
ES2516694T3 (es) * | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
BRPI0809670A8 (pt) | 2007-04-03 | 2018-12-18 | Biogenerix Ag | métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral. |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
US10383919B1 (en) * | 2013-05-31 | 2019-08-20 | The University of the Sciences | Fragments of growth hormone binding protein |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
-
1994
- 1994-04-07 US US08/224,982 patent/US5646113A/en not_active Expired - Lifetime
-
1995
- 1995-03-24 DK DK95914872T patent/DK0754048T3/da active
- 1995-03-24 PT PT95914872T patent/PT754048E/pt unknown
- 1995-03-24 JP JP52635695A patent/JP3366644B2/ja not_active Expired - Lifetime
- 1995-03-24 WO PCT/US1995/003731 patent/WO1995027495A2/en active IP Right Grant
- 1995-03-24 AT AT95914872T patent/ATE203165T1/de active
- 1995-03-24 ES ES95914872T patent/ES2160704T3/es not_active Expired - Lifetime
- 1995-03-24 DE DE69521796T patent/DE69521796T2/de not_active Expired - Lifetime
- 1995-03-24 MX MX9604635A patent/MX9604635A/es unknown
- 1995-03-24 MX MX9701916A patent/MX9701916A/es unknown
- 1995-03-24 CA CA002187274A patent/CA2187274C/en not_active Expired - Lifetime
- 1995-03-24 EP EP95914872A patent/EP0754048B1/en not_active Expired - Lifetime
-
2000
- 2000-01-07 JP JP2000001444A patent/JP2000226334A/ja active Pending
-
2001
- 2001-10-16 GR GR20010401771T patent/GR3036901T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0754048A1 (en) | 1997-01-22 |
JPH09509430A (ja) | 1997-09-22 |
ES2160704T3 (es) | 2001-11-16 |
GR3036901T3 (en) | 2002-01-31 |
DK0754048T3 (da) | 2001-11-05 |
US5646113A (en) | 1997-07-08 |
MX9701916A (es) | 1997-06-28 |
WO1995027495A3 (en) | 1995-12-28 |
JP2000226334A (ja) | 2000-08-15 |
CA2187274C (en) | 2001-01-02 |
PT754048E (pt) | 2002-01-30 |
EP0754048B1 (en) | 2001-07-18 |
WO1995027495A2 (en) | 1995-10-19 |
ATE203165T1 (de) | 2001-08-15 |
JP3366644B2 (ja) | 2003-01-14 |
DE69521796D1 (de) | 2001-08-23 |
DE69521796T2 (de) | 2002-05-23 |
CA2187274A1 (en) | 1995-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9604635A (es) | Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento. | |
SE8703625D0 (sv) | New medical use | |
IL154797A0 (en) | Vascular endothelial cell growth factor that is unaccompanied by associated native glycosylation, pharmaceutical composition containing it and use thereof in the manufacture of a medicament for treating trauma affecting the vascular endothelium | |
NZ227788A (en) | Peptide having growth hormone regulatory effects, and compositions | |
CA2285203A1 (en) | Compositions containing capsaicin or capsaicin analogues and a local anesthetic | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
NO940180D0 (no) | Anvendelse av IGF-I | |
UA27035C2 (uk) | Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму | |
PT914148E (pt) | Tratamento do sindroma de insensibilidade parcial a hormona de crescimento | |
HU9202092D0 (en) | An implantate composition containing biologically active protein, peptide or polypeptide | |
DE69326122D1 (de) | Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen | |
DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
ATE251640T1 (de) | Neues chondrozytprotein | |
NO20000007D0 (no) | Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet | |
DE69113773D1 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
DE69927599D1 (de) | Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie |